| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ghayyur Khalil, Feroz A Khan, Qazi M Jamal, Ayesha Saleem, Hassan Masroor, Kiran Abba. Change in Insulin Sensitivity and Lipid Profile After Dopamine Agonist Therapy in Patients With Prolactinoma. Cureus. vol 13. issue 9. 2021-10-22. PMID:34660034. |
change in insulin sensitivity and lipid profile after dopamine agonist therapy in patients with prolactinoma. |
2021-10-22 |
2023-08-13 |
Not clear |
| Ghayyur Khalil, Feroz A Khan, Qazi M Jamal, Ayesha Saleem, Hassan Masroor, Kiran Abba. Change in Insulin Sensitivity and Lipid Profile After Dopamine Agonist Therapy in Patients With Prolactinoma. Cureus. vol 13. issue 9. 2021-10-22. PMID:34660034. |
we aimed to find the change in insulin sensitivity and lipid profile in prolactinoma patients after dopamine therapy. methodology a prospective observational study was conducted at the hayatabad medical complex, peshawar between june 2019 to july 2020. |
2021-10-22 |
2023-08-13 |
Not clear |
| Ghayyur Khalil, Feroz A Khan, Qazi M Jamal, Ayesha Saleem, Hassan Masroor, Kiran Abba. Change in Insulin Sensitivity and Lipid Profile After Dopamine Agonist Therapy in Patients With Prolactinoma. Cureus. vol 13. issue 9. 2021-10-22. PMID:34660034. |
further studies should explore the long-term side effects of dopamine agonists on patients with prolactinoma. |
2021-10-22 |
2023-08-13 |
Not clear |
| Peter I Dosa, Tim Ward, Michael A Walters, Suck Won Ki. Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism. ACS medicinal chemistry letters. vol 4. issue 2. 2021-10-21. PMID:23606928. |
the dopamine agonist cabergoline has been used to treat prolactinomas, parkinson's disease, cushing's disease and sexual dysfunction. |
2021-10-21 |
2023-08-12 |
Not clear |
| Yae Won Park, Jihwan Eom, Sooyon Kim, Hwiyoung Kim, Sung Soo Ahn, Cheol Ryong Ku, Eui Hyun Kim, Eun Jig Lee, Sun Ho Kim, Seung-Koo Le. Radiomics With Ensemble Machine Learning Predicts Dopamine Agonist Response in Patients With Prolactinoma. The Journal of clinical endocrinology and metabolism. vol 106. issue 8. 2021-10-18. PMID:33713414. |
radiomics with ensemble machine learning predicts dopamine agonist response in patients with prolactinoma. |
2021-10-18 |
2023-08-13 |
Not clear |
| Yae Won Park, Jihwan Eom, Sooyon Kim, Hwiyoung Kim, Sung Soo Ahn, Cheol Ryong Ku, Eui Hyun Kim, Eun Jig Lee, Sun Ho Kim, Seung-Koo Le. Radiomics With Ensemble Machine Learning Predicts Dopamine Agonist Response in Patients With Prolactinoma. The Journal of clinical endocrinology and metabolism. vol 106. issue 8. 2021-10-18. PMID:33713414. |
early identification of the response of prolactinoma patients to dopamine agonists (da) is crucial in treatment planning. |
2021-10-18 |
2023-08-13 |
Not clear |
| Lakshmi P Menon, Wedad Rahma. Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma. Journal of investigative medicine high impact case reports. vol 9. 2021-10-15. PMID:34218714. |
dopamine agonists are generally well tolerated and represent the first-line therapy for prolactinomas. |
2021-10-15 |
2023-08-13 |
Not clear |
| Hande Mefkure Ozkaya, Serdar Sahin, Ozge Polat Korkmaz, Emre Durcan, Humeyra Rekali Sahin, Emir Celik, Burc Cagri Poyraz, Pinar Kadiogl. Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 55. 2021-10-12. PMID:33010581. |
patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas. |
2021-10-12 |
2023-08-13 |
Not clear |
| Hande Mefkure Ozkaya, Serdar Sahin, Ozge Polat Korkmaz, Emre Durcan, Humeyra Rekali Sahin, Emir Celik, Burc Cagri Poyraz, Pinar Kadiogl. Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 55. 2021-10-12. PMID:33010581. |
to evaluate the prevalence of impulse control disorders (icd) and psychiatric symptoms in patients with acromegaly receiving dopamine agonists (da) in comparison with those with prolactinoma, nonfunctioning pituitary adenomas (nfa), and healthy controls (hc). |
2021-10-12 |
2023-08-13 |
Not clear |
| Busra Aydin, Aysegul Caliskan, Kazim Yalcin Arg. Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies. The EPMA journal. vol 12. issue 3. 2021-09-29. PMID:34567287. |
despite the good response of prolactinomas to dopamine agonist therapy, some of these tumors persist or recur; also, about 20% are resistant and 10% behave aggressively. |
2021-09-29 |
2023-08-13 |
Not clear |
| Ingrid M Zandbergen, Amir H Zamanipoor Najafabadi, Iris C M Pelsma, M Elske van den Akker-van Marle, Peter H L T Bisschop, H D Jeroen Boogaarts, Arianne C van Bon, Bakhtyar Burhani, Saskia le Cessie, Olaf M Dekkers, Madeleine L Drent, Richard A Feelders, Johan P de Graaf, J Hoogmoed, Kitty K Kapiteijn, Melanie M van der Klauw, Willy-Anne C M Nieuwlaat, Alberto M Pereira, Aline M E Stades, Annenienke C van de Ven, Iris M M J Wakelkamp, Wouter R van Furth, Nienke R Biermas. The PRolaCT studies - a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma. Trials. vol 22. issue 1. 2021-09-28. PMID:34563236. |
first-line treatment for prolactinomas is a medical treatment with dopamine agonists (das), which effectively control hyperprolactinaemia in most patients, although post-withdrawal remission rates are approximately 34%. |
2021-09-28 |
2023-08-13 |
Not clear |
| Júlia Vieira Oberger Marques, Cesar Luiz Boguszewsk. Fertility issues in aggressive pituitary tumors. Reviews in endocrine & metabolic disorders. vol 21. issue 2. 2021-09-27. PMID:31984458. |
the initial approach to restore fertility involves the reduction of tumor volume by the use of dopamine agonists in prolactinomas and by surgery in other pituitary adenomas. |
2021-09-27 |
2023-08-13 |
Not clear |
| Odelia Cooper, Vivien S Bonert, Jeremy Rudnick, Barry D Pressman, Janet Lo, Roberto Salvatori, Kevin C J Yuen, Maria Fleseriu, Shlomo Melme. EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas. The Journal of clinical endocrinology and metabolism. vol 106. issue 2. 2021-09-20. PMID:33150390. |
approximately 10% to 20% of prolactinomas are resistant to dopamine agonist therapy. |
2021-09-20 |
2023-08-13 |
Not clear |
| Lin Cai, Jian Chen, Jianglong Lu, Qun Li, Xianbin Chen, Linlin Zhang, Jinsen Wu, Weiming Zheng, Chengde Wang, Zhipeng S. Tumor stem-like cells isolated from MMQ cells resist to dopamine agonist treatment. Molecular and cellular endocrinology. vol 535. 2021-09-16. PMID:34271069. |
here, we identified a small subset of sphere-forming cells possess tumor stem-like cell properties in rat prolactinoma mmq cells, which resist to dopamine agonist treatment. |
2021-09-16 |
2023-08-13 |
rat |
| Jianglong Lu, Lin Cai, Zerui Wu, Weiwei Lin, Jiadong Xu, Zhangzhang Zhu, Chengde Wang, Qun Li, Zhipeng S. Surgery and Medical Treatment in Microprolactinoma: A Systematic Review and Meta-Analysis. International journal of endocrinology. vol 2021. 2021-09-11. PMID:34504526. |
dopamine agonists (das) are recommended as the first-line treatment for prolactinomas; however, tumour recurrence after drug withdrawal remains a clinical problem. |
2021-09-11 |
2023-08-13 |
Not clear |
| Kyungwon Kim, Yae Won Park, Daham Kim, Sung Soo Ahn, Ju Hyung Moon, Eui Hyun Kim, Eun Jig Lee, Cheol Ryong K. Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma. The Journal of clinical endocrinology and metabolism. vol 106. issue 2. 2021-09-08. PMID:33079168. |
dopamine agonists (das) are the first-line therapy for prolactinomas. |
2021-09-08 |
2023-08-13 |
Not clear |
| b' Betina Biagetti, Silvana Sarria-Estrada, Yiken Karelys Ng-Wong, Elena Martinez-Saez, Anna Caster\\xc3\\xa0s, Esteban Cordero Asanza, Irene Hernandez, Marina Giralt-Arnaiz, Rafael Sim\\xc3\\xb. Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline. European journal of endocrinology. vol 185. issue 4. 2021-09-08. PMID:34374649.' |
transsphenoidal surgery (tss) is mainly indicated in prolactinomas when dopamine agonist treatment fails. |
2021-09-08 |
2023-08-13 |
Not clear |
| Marisa C Penn, Tyler Cardinal, Yanchen Zhang, Brittany Abt, Phillip A Bonney, Patricia Lorenzo, Michelle Lin, Jack Rosner, Martin Weiss, Gabriel Zada, John D Carmichae. Cure and Hormonal Control After Prolactinoma Resection: Case Series and Systematic Review. Journal of the Endocrine Society. vol 5. issue 10. 2021-09-03. PMID:34466765. |
surgical management of prolactinomas is an important treatment for patients intolerant of dopamine agonist therapy. |
2021-09-03 |
2023-08-13 |
Not clear |
| Yan Ting Liu, Fang Liu, Lei Cao, Li Xue, Wei Ting Gu, Yong Zhi Zheng, Hao Tang, Yu Wang, Hong Yao, Yong Zhang, Wan Qun Xie, Bo Han Ren, Zhuo Hui Xiao, Ying Jie Nie, Ronggui Hu, Zhe Bao W. The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment. Acta neuropathologica. vol 140. issue 3. 2021-08-06. PMID:32572597. |
dopamine agonists (das), such as cabergoline (cab), have been successfully used in the treatment of prolactinomas. |
2021-08-06 |
2023-08-13 |
mouse |
| Gamze Akkus, Barış Karagun, Hilal Nur Yaldız, Mehtap Evran, Murat Sert, Tamer Tetike. Outcomes of surgical and/or medical treatment in patients with prolactinomas during long-term follow-up: a retrospective single-centre study. Hormone molecular biology and clinical investigation. vol 42. issue 2. 2021-08-02. PMID:34332519. |
current medical guidelines recommend dopamine agonists (cabergoline or bromocriptine) as the initial therapy for prolactinoma. |
2021-08-02 |
2023-08-13 |
Not clear |